SCHEMBL172412

SCHEMBL172412

Cc1cc(C(C)O)ccc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 6/20 0.50
TP53 P04637 1/20 0.50
KDM4E B2RXH2 5/20 0.48
MAPT P10636 5/20 0.48
RECQL P46063 4/20 0.48
LMNA P02545 3/20 0.48
MTOR P42345 3/20 0.48
HIF1A Q16665 3/20 0.48
TSHR P16473 2/20 0.48
NFKB1 P19838 2/20 0.48
HSD17B10 Q99714 2/20 0.48
KMT2A Q03164 2/20 0.48
ALOX15 P16050 1/20 0.48
THPO P40225 1/20 0.48
POLB P06746 1/20 0.48
APEX1 P27695 1/20 0.48
BLM P54132 1/20 0.48
TRPA1 O75762 1/20 0.48
PTGS1 P23219 1/20 0.48
CACNA1C Q13936 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL7106413 0.98 TDP1 (0.48) TDP1TP53KDM4EMAPTRECQL
SCHEMBL28878142 0.84 TDP1 (0.52) TDP1TP53KDM4EMAPTRECQL
SCHEMBL921090 0.84 TDP1 (0.52) TDP1TP53KDM4EMAPTRECQL
SCHEMBL1397101 0.84 PTGS1 (0.68) TDP1TP53KDM4EMAPTRECQL
SCHEMBL29657745 0.84 TDP1 (0.52) TDP1TP53KDM4EMAPTRECQL
SCHEMBL283463 0.84 TDP1 (0.52) TDP1TP53KDM4EMAPTRECQL
SCHEMBL29948126 0.84 TDP1 (0.52) TDP1TP53KDM4EMAPTRECQL
SCHEMBL19117132 0.84 HSD17B1 (0.55) TDP1TP53KDM4ERECQLLMNA
SCHEMBL29525823 0.83 TDP1 (0.65) TDP1KDM4EMAPTRECQLLMNA
SCHEMBL241136 0.83 TDP1 (0.65) TDP1KDM4EMAPTRECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10040777-B2 Polymers, co-polymers, and monomers using CO2 as a reagent EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2018-08-07 US claimed
US-20150376331-A1 POLYMERS, CO-POLYMERS, AND MONOMERS USING CO2 AS A REAGENT CRESTLINE DIRECT FINANCE, L.P. 2015-12-31 US claimed
EP-0836628-B1 PROCESS FOR PREPARING POLYHYDROXYSTYRENE WITH A NOVOLAK TYPE STRUCTURE TRIQUEST L P (US) 2003-10-15 EP claimed
WO-1997034197-A1 RESIN COMPOSITIONS FOR PHOTORESIST APPLICATIONS HOECHST CELANESE CORPORATION (US) 1997-09-18 WO claimed
WO-1997000465-A1 RESIN COMPOSITIONS FOR PHOTORESIST APPLICATIONS CLARIANT INTERNATIONAL LTD. (CH) 1997-01-03 WO claimed
US-5565544-A POLYMERIZING A MIXTURE OF CARBOXYLIC ACID AND AT LEAST ONE SUSTITUTED PHENYL CARBINOL HOECHST CELANESE CORPORATION (US) 1996-10-15 US claimed
US-5554719-A Polyhydroxystyrene with a novolak type structure HOECHST CELANESE CORPORATION (US) 1996-09-10 US claimed
US-20230348351-A1 COMPOUND, POLYMER, COMPOSITION, COMPOSITION FOR FILM FORMATION, PATTERN FORMATION METHOD, INSULATING FILM FORMATION METHOD, AND METHOD FOR PRODUCING COMPOUND MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2023-11-02 US disclosed
WO-2022138670-A1 COMPOUND, POLYMER, COMPOSITION, FILM-FORMING COMPOSITION, PATTERN FORMATION METHOD, METHOD FOR FORMING INSULATING FILMS, AND COMPOUND PRODUCTION METHOD 三菱瓦斯化学株式会社 2022-06-30 WO disclosed
US-10040777-B2 Polymers, co-polymers, and monomers using CO2 as a reagent EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2018-08-07 US disclosed
US-20150376331-A1 POLYMERS, CO-POLYMERS, AND MONOMERS USING CO2 AS A REAGENT CRESTLINE DIRECT FINANCE, L.P. 2015-12-31 US disclosed
US-20150237900-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE CHROMOCELL CORP (US) 2015-08-27 US disclosed
WO-2013186358-A1 ASYMMETRIC HYDRATION OF 4-HYDROXYSTYRENE DERIVATIVES EMPLOYING DECARBOXYLASES ACIB GMBH (AT) 2013-12-19 WO disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed
EP-0836628-B1 PROCESS FOR PREPARING POLYHYDROXYSTYRENE WITH A NOVOLAK TYPE STRUCTURE TRIQUEST L P (US) 2003-10-15 EP disclosed
EP-0836628-A1 PROCESS FOR PREPARING POLYHYDROXYSTYRENE WITH A NOVOLAK TYPE STRUCTURE HOECHST CELANESE CORPORATION (US) 1998-04-22 EP disclosed
WO-1997000278-A1 PROCESS FOR PREPARING POLYHYDROXYSTYRENE WITH A NOVOLAK TYPE STRUCTURE HOECHST CELANESE COPORATION (US) 1997-01-03 WO disclosed
US-5565544-A POLYMERIZING A MIXTURE OF CARBOXYLIC ACID AND AT LEAST ONE SUSTITUTED PHENYL CARBINOL HOECHST CELANESE CORPORATION (US) 1996-10-15 US disclosed
US-5554719-A Polyhydroxystyrene with a novolak type structure HOECHST CELANESE CORPORATION (US) 1996-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348351-A1 COMPOUND, POLYMER, COMPOSITION, COMPOSITION FOR FILM FORMATION, PATTERN FORMATION METHOD, INSULATING FILM FORMATION METHOD, AND METHOD FOR PRODUCING COMPOUND PHOSPHO1, RER1, RIF1 TDP1 2166/4885TP53 4245/4885KDM4E 238/4885
US-20150376331-A1 POLYMERS, CO-POLYMERS, AND MONOMERS USING CO2 AS A REAGENT MACF1, PARG, PPOX TDP1 3484/4885TP53 3325/4885KDM4E 3454/4885
US-10040777-B2 Polymers, co-polymers, and monomers using CO2 as a reagent MACF1, PARG, PPOX TDP1 3484/4885TP53 3325/4885KDM4E 3454/4885
US-20150237900-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE TAS2R5, TAS2R20, TAS2R10 TDP1 3251/4885TP53 4019/4885KDM4E 2256/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA TDP1 2714/4885TP53 165/4885KDM4E 2305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.